AstraZeneca Buys Rare Disease Drugmaker For Up To $500M
AstraZeneca said Wednesday it will buy the remaining equity of Caelum Biosciences in a deal steered by DLA Piper, Alston & Bird and Foley Hoag that's worth up to $500 million,...To view the full article, register now.
Already a subscriber? Click here to view full article